Significant Side Effects Of Treatment Research Articles

Experience of X-linked hypophosphatemic rickets in the Gulf Cooperation Council countries: case series.

X-linked hypophosphatemic rickets (XLH), the most prevalent form of inherited hypophosphatemic rickets, is caused by loss-of-function mutations in the gene encoding phosphate-regulating endopeptidase homolog, X-linked (PHEX). This case series presents 14 cases of XLH from Gulf Cooperation Council (GCC) countries. The patients' medical history, biochemical and radiological investigative findings, as well as treatment responses and side effects from both conventional and burosumab therapy, are described. Cases were aged 2-40 years at diagnosis. There were two male cases and 12 female cases. All cases were treated with conventional therapy which resulted in a lack of improvement in or worsening of the clinical signs and symptoms of rickets or biochemical parameters. Side effects of conventional therapy included nausea, diarrhea, abdominal pain, nephrocalcinosis, and hyperparathyroidism, which affected the patients' quality of life and adherence to treatment. In the 10 patients treated with burosumab, there was a marked improvement in the biochemical markers of rickets, with a mean increase in serum phosphate of +0.56 mmol/L and tubular maximum phosphate reabsorption (TmP) to glomerular filtration rate (GFR) ratio (TmP/GFR) of +0.39 mmol/L at 12 months compared to baseline. Furthermore, a mean decrease in serum alkaline phosphatase (ALP) of -80.80 IU/L and parathyroid hormone (PTH) of -63.61 pmol/L at 12 months compared to baseline was observed in these patients. Additionally, patients treated with burosumab reported reduced pain, muscle weakness, and fatigue as well as the ability to lead more physically active lives with no significant side effects of treatment. Conventional therapy resulted in a suboptimal response, with a lack of improvement of clinical signs and symptoms. Side effects of conventional therapy included nausea, diarrhea, abdominal pain, nephrocalcinosis, and hyperparathyroidism, which affected the patients' quality of life and adherence to treatment. Burosumab demonstrated marked improvements in the biochemical markers of rickets, in addition to reducing pain, muscle weakness, and fatigue. There were no significant side effects associated with burosumab therapy.

"It doesn't really apply to what I'm going through": a mixed-methods study of barriers to palliative care among patients with advanced ovarian cancer.

Palliative care aims to provide symptom relief and general support for patients with serious illness. Despite experiencing significant treatment side effects, specialty palliative care is under-utilized by patients with advanced ovarian cancer. We explored barriers to palliative care in this population. We conducted a sequential mixed-methods study. Qualitative: we interviewed patients with advanced ovarian cancer (N = 7). Guided by the Social Ecological Model (SEM), interviews assessed intrapersonal, interpersonal, organizational, and policy-level barriers to receipt of specialty palliative care. Interviews were audio-recorded, transcribed, and analyzed with directed content analysis. Quantitative: patients with advanced ovarian cancer (N = 38) completed self-report surveys assessing knowledge about, attitudes towards, and prior experiences with specialty palliative care. Descriptive statistics were used to characterize survey responses. Qualitative analysis identified barriers to specialty palliative care at each SEM level. Intrapersonal factors (e.g., knowledge, attitudes) were most frequently discussed. Other common barriers included insurance coverage and distance/travel time. Survey responses indicated most participants were aware of palliative care (74%) but had mixed attitudes towards palliative care and did not feel they needed for palliative care. No survey respondents had received a physician recommendation for palliative care, and a sizable minority (29%) thought palliative care referral should only take place when patients have no remaining treatment options. Among patients with advanced ovarian cancer, barriers to specialty palliative care exist at multiple levels. Our results underscore the potential value of a multilevel intervention to support receipt of palliative care in this population.

Assessment of Extractions of Deciduous Mandibular Canine Teeth to Correct Linguoversion Malocclusion in 17 Dogs.

A search of medical records at the Center for Veterinary Dentistry and Oral Surgery, Gaithersburg, MD was conducted to identify patients who received extractions of deciduous mandibular canine teeth to treat linguoversion. Patients were included if they were less than 5.5 months of age and had a diagnosis of deciduous class 2 or bilateral class 1 malocclusions. Treatment was considered a success if normocclusion of the permanent dentition was achieved at follow up evaluation. Seventeen patients represented 13 different breeds. No significant correlation was seen between age of treatment (mean age 3.34 months) or sex (11 males, 6 females). Six patients had class 1 malocclusions (35.29%) and eleven patients had class 2 malocclusion (64.71%). Of the six dogs treated for class 1 malocclusions, two had traumatic palatal contact and four had only minor soft tissue contact. Eleven cases of class 2 malocclusion were treated and of these there was one mild, six moderate, and four severe cases of mandibular distocclusion. All cases treated for class 1 malocclusions had a successful outcome resulting in permanent normocclusion (100%), while class 2 malocclusions had success in three of eleven cases (27.27%). The outcomes based on occlusion type were determined to be significant (p = 0.009). All participants had immediate relief of soft tissue trauma and no significant side effects of treatment were recorded. The results show that extractions of deciduous linguoverted mandibular canine teeth (LMC) can immediately improve traumatic impingement and may be a factor in providing a comfortable and functional adult occlusion. Further investigation with a larger sample size would be warranted.

DDRE-02. PATIENTS WITH LEPTOMENINGEAL METASTASES FROM NSCLC BENEFITED FROM INTRATHECAL PEMETREXED AFTER FAILURE TO TYROSINE KINASE INHIBITORS: TWO CASE REPORTS

Abstract BACKGROUND The incidence of leptomeningeal metastasis (LM) is 3%-5% in NSCLC patients; the incidence is even higher in patients with EGFR mutations or ALK gene rearrangement. The prognosis of NSCLC patients with LM is poor with an overall survival (OS) of 3 months with contemporary treatment. METHODS Here we report two cases of patients with leptomeningeal metastases from NSCLC who benefited from intrathecal pemetrexed after failure to tyrosine kinase inhibitors(TKIs). RESULTS A 53-year-old woman, diagnosed with adenocarcinoma of the lung with ALK rearrangement, suffered form right limb weakness, dysphagia after multi-line targeted therapy and radiotherapy for brain metastases. Evaluation revealed a rapidly progressing right brainstem mass and diffuse leptomeningeal enhanced. And cytological examination of CSF showed neoplastic cells, which definitely diagnosed as LM. After first intrathecal injection of 30mg pemetrexed every three weeks, the patient's symptoms improved. There were no significant treatment side effects and the quality of life was not affected during the five subsequent treatments. Another patient was a 32-year-old man, diagnosed with adenocarcinoma of the lung with EGFR E24-RAD51E4 fusion mutation with KPS score 30. LM was confirmed after multiline therapy. He suffered form blurred vision and drooping eyelid. Similarly, after first intrathecal injection of 20mg pemetrexed every week, the patient's symptoms improved and KPS score increased gradually. And level II leukopenia was detected during subsequent treatments. Combined with intrathecal pemetrexed progression-free survival (PFS) were 3 months in two NSCLC patients with LM harboring ALK/EGFR mutation . And the quality of life of patients were effectively increased. CONCLUSION Combination therapy third generation EGFR/ALK agents with intrathecal chemotherapy might be benefited in overall survival.

Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.

Autoimmune diabetes mellitus is a rare but significant side effect of treatment with immune checkpoint inhibitors. Immune checkpoint inhibitor-induced diabetes mellitus (CPI-DM) is characterized by acute onset of dramatic hyperglycemia with severe insulin deficiency and occurrence following exposure to programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors rather than cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors. As a growing number of patients undergo immunotherapy, further understanding of the characteristics of CPI-DM patients is needed for improved prognostic and diagnostic application in order to reduce overall morbidity for this already at-risk population. Additionally, understanding of the features and mechanisms of CPI-DM may contribute to understanding mechanisms of spontaneous type I diabetes mellitus (T1DM). Here, we summarize the clinical features of CPI-DM and interrogate the genetic and cellular mechanisms that may contribute to the disease, as well as the clinical challenges for predicting and treating these patients as increasing cancer immunotherapies reach clinical utility.

Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report

BackgroundSevere epistaxis is often difficult to control in patients with hereditary hemorrhagic telangiectasia (HHT). Propranolol has been shown to have antiangiogenic properties in vitro and in vivo and is commonly used to treat hemangiomas. We present our experience with topical nasal propranolol for the treatment of moderate to severe epistaxis in patients with HHT.MethodsRetrospective case series. Six patients with HHT were treated with 0.5 cm3 of 1.5% propranolol gel, applied to each nostril twice daily for at least 12 weeks. Outcome measures were epistaxis severity score (ESS), hemoglobin level, and number of blood transfusions prior to and while on treatment. Local and systemic side effects were recorded.ResultsThe mean duration of treatment was 30 ± 5.6 weeks. A significant improvement in the ESS was found in all patients, with a mean decrease from 6.4 ± 2.1 at treatment onset to 3.5 ± 1.7 at 12 weeks (p = 0.028). Hemoglobin level increased significantly from 8.4 ± 3.1 to 11.0 ± 1.8 g/dL at 12 weeks (p = 0.043). The mean number of blood transfusions decreased from 4.5 ± 4.9 before treatment to 2.5 ± 2.9 at 12 weeks and 0.3 ± 0.8 at 24 weeks, but the difference did not reach statistical significance (p = 0.109 for both). No significant side effects of treatment were recorded.ConclusionsThese preliminary results suggest that topical propranolol may be effective for the treatment of epistaxis in patients with HHT. A prospective controlled trial is required to confirm our findings.

High-risk corneal allografts: A therapeutic challenge.

Corneal transplantation is the most common surgical procedure amongst solid organ transplants with a high survival rate of 86% at 1-year post-grafting. This high success rate has been attributed to the immune privilege of the eye. However, mechanisms originally thought to promote immune privilege, such as the lack of antigen presenting cells and vessels in the cornea, are challenged by recent studies. Nevertheless, the immunological and physiological features of the cornea promoting a relatively weak alloimmune response is likely responsible for the high survival rate in "low-risk" settings. Furthermore, although corneal graft survival in "low-risk" recipients is favourable, the prognosis in "high-risk" recipients for corneal graft is poor. In "high-risk" grafts, the process of indirect allorecognition is accelerated by the enhanced innate and adaptive immune responses due to pre-existing inflammation and neovascularization of the host bed. This leads to the irreversible rejection of the allograft and ultimately graft failure. Many therapeutic measures are being tested in pre-clinical and clinical studies to counter the immunological challenge of "high-risk" recipients. Despite the prevailing dogma, recent data suggest that tissue matching together with use of systemic immunosuppression may increase the likelihood of graft acceptance in "high-risk" recipients. However, immunosuppressive drugs are accompanied with intolerance/side effects and toxicity, and therefore, novel cell-based therapies are in development which target host immune cells and restore immune homeostasis without significant side effect of treatment. In addition, developments in regenerative medicine may be able to solve both important short comings of allotransplantation: (1) graft rejection and ultimate graft failure; and (2) the lack of suitable donor corneas. The advances in technology and research indicate that wider therapeutic choices for patients may be available to address the worldwide problem of corneal blindness in both "low-risk" and "high-risk" hosts.

Evaluation of the effectiveness of treatment with prednisone and azathioprine of autoimmune hepatitis in children.

IntroductionAutoimmune hepatitis is rarely diagnosed in children, but the course of the disease is often aggresive. Combination therapy with prednisone and azathioprine improves the prognosis of patients.AimTo evaluate the effectiveness of combination therapy with prednisone and azathioprine of autoimmune hepatitis (AIH) in children.Material and methodsThere was a retrospective analysis of the medical records of 15 patients with AIH, diagnosed before18 years of age, treated in the Provincial Infectious Diseases Hospital in Bydgoszcz in the years 2002 to 2013. We analysed the results of laboratory tests, ultrasound examination, endoscopy, and morphological liver pictures, as well as periods of exacerbation of inflammation and side effects of therapy.ResultsBiochemical remission of the disease was achieved on average after 36 days of treatment. Histopathological regression in the control liver biopsy was found in 7/15 patients and progression in 2/15 patients. In the study group 10/15 patients experienced exacerbation of the disease from 1 to 3 times during observation, with an increase of ALT activity to greater than 3 norm, and the remaining 5/15 patients had no increase of ALT activity. In total, 10 patients in the study group experienced 17 exacerbations. In 13/17 cases of exacerbations they were associated with a reduction in the dose of immunosuppressive drugs. There was no correlation between the biochemical exacerbation and changes in the histopathological image. Steroidside effects occurred in 14/15 patients.ConclusionsThe treatment allows for biochemical remission of the disease and significantly improves the prognosis of most patients. However, significant side effects of treatment indicate the need for further exploration of effective and safe therapy, especially in the paediatric population.

A systematic review of patient preference elicitation methods in the treatment of colorectal cancer.

This systematic review aimed to assess the use of patient preference in colorectal cancer treatment. Eliciting patient preference is important for shared decision-making in colorectal cancer treatment. The introduction of newer treatments, which balance quality of life and overall survival, makes this an important future focus. A systematic search strategy of MEDLINE, Embase, PsycINFO, CINAHL and the Cochrane Database for Systematic Reviews was undertaken to obtain relevant articles. Information regarding the type of patients included, preference instruments, study settings, outcomes and limitations was extracted. The eight articles comprising this review each described an empirical study using a validated instrument to define patient preference for an aspect of colorectal cancer treatment. The evidence suggests that patients are prepared to trade significant reductions in life expectancy to avoid certain complications of colorectal surgery, particularly stoma formation. In the adjuvant setting, patients are prepared to risk significant treatment side effects to gain small potential increases in life expectancy and chance of survival. Where neoadjuvant or adjuvant treatment risks worsening function, however, patients generally forgo any potential increase in survival to improve bowel function and therefore quality of life. The only predictors of preference were tertiary education and previous cancer treatment. Most patients judge a moderate survival benefit to be sufficient to make adjuvant therapy for colorectal cancer worthwhile, but they are willing to trade a potential reduction in life expectancy and survival to avoid certain unwanted surgical sequelae.

Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: A 5-year follow-up

The aim of this study was to evaluate the outcome of mycophenolate mofetil (MMF) therapy in children with autoimmune liver disease who are resistant to or intolerant of standard immunosuppression. (a) failure to achieve/maintain remission with prednisolone/azathioprine therapy or (b) significant treatment side-effects. Initial MMF dose was 20mg/kg/day, gradually increased to a maximum of 40 mg/kg/day. Azathioprine was stopped when MMF was commenced. Twenty-six children (17 female) were recruited. Median (range) age at diagnosis was 9.9 (1.2-14.4) years. Sixteen had Type 1 autoimmune hepatitis (AIH), two Type 2 AIH, and eight had autoimmune sclerosing cholangitis (ASC). Median (range) time from diagnosis to addition of MMF was 14.9 (0.2-108.6) months. Eighteen children responded to MMF, aspartate aminotransferase (AST) normalising in 14. At median (range) follow-up of 61.5 (19.5-96.3) months, AST remained normal in 12. All 18 children were well, but two had clinical signs of portal hypertension. Eight (6 ASC) did not respond: AST remained elevated in seven, one was listed for transplant for decompensated liver disease and one had clinical signs of portal hypertension. MMF was well tolerated. Leukopenia (n=7) was the most common side-effect. MMF is an effective rescue therapy for children with AIH, but not for those with ASC.

Case reports: an opportunity for early intervention: velo‐cardio‐facial syndrome and psychosis

Velo-cardio-facial syndrome is the most common micro deletion syndrome in man, with the typically deleted region in the 22q11area, an area that contains many genes with possible links to mental illnesses. The syndrome phenotype includes multiple physical abnormalities, learning disorders and a greatly increased risk of developing a psychotic disorder. A series of three cases is presented to describe some of the psychiatric manifestations of the velo-cardio-facial syndrome. The three young people presented here all had an illness of long duration that was difficult to treat, with significant side effects of treatment and varying degrees of recovery. As more children with genetic syndromes are identified early and monitored by genetic clinics and other paediatric services, there is an opportunity for psychiatric services to provide early intervention for a group of patients who are likely to have a poor response to treatment if they present with an advanced psychosis. Studying the deletions in the 22q11 area also has great potential for investigating possible causes of a genetic vulnerability to psychotic illness.

Nurse-led formal health review for immunosuppressed patients with uveitis

To describe and analyse a method of detailed formal health review for patients with sight-threatening uveitis using oral immunosuppression. Prospective clinical study of 37 patients. Treatment side effects were absent or tolerable in 31 patients (84%) but 34 significant treatment side effects or other significant clinical findings were newly identified. Ten patients underwent a treatment change including three who transferred to a different immunosuppressive. Formal health review has proved useful in identifying treatment side effects previously not volunteered by patients. A modified form is to be embedded within our clinic management system. We recommend such reviews to enhance drug safety in patients with sight-threatening chronic uveitis using oral immunosuppressives.

How Early in Treatment is PAP Adherence Established? Revisiting Night-to-Night Variability

Obstructive sleep apnea (OSA) is a serious disorder with significant daytime consequences. Treatment for OSA most commonly takes the form of positive airway pressure (PAP). Although effective, PAP adherence is often below expectations. Previous studies have suggested that early PAP use can predict long-term adherence, but these studies have not been replicated, nor has follow up been longer than 3 months. This article presents a replication study enhanced by a longer follow up and additional data to suggest that 6-month adherence can be predicted within the first days of PAP use. This article also discusses how this might relate to the experience of significant side effects of treatment.

European study of the antenatal management of fetomaternal alloimmune thrombocytopenia (FMAIT)

FMAIT occurs in ∼1 in 1200 births, of which 10–20% have serious bleeding, i.e. intracranial haemorrhage (ICH). Management of such pregnancies needs to balance the risk of bleeding against the known risk of fetal blood sampling (FBS). S tudy This was a nonrandomised observational study of FMAIT due to anti-HPA-1a. All cases were managed by an initial FBS, then a) intravenous immunoglobulin (IVIgG), b) regular intrauterine platelet transfusions (IUT), c) neither of above, but FBS ± 1 IUT predelivery, d) no treatment. All babies with a previous sibling known to have platelets < 20 × 109/L or an ICH were considered high risk. R esults 43 pregnancies (44 babies) were analysable giving 49 results in total (more than 1 management in 5). In (a) there was one case with ICH. The resultant platelet count was ≥ 50 × 109/L in 10 cases, and 6 of these were high risk (5 ICH, 1plts < 20 × 109/L). No significant side-effects of treatment occurred. In (b) the number of high risk cases was greater than (a) and there were 2 cases of ICH. The pre-IUT platelet count was < 20 × 109/L on at least 50% of occasions in 10 cases. Overall 12 babies needed to be delivered because of complications caused by FBS/IUT, 4 at less than 32 weeks gestation. There were few cases in (c) and no cases in (d). C onclusions The incidence of ICH in the study group is less than the incidence of ICH in untreated siblings. However, complications from FBS/IUT were significant, and the platelet count was not consistently maintained at > 20 × 109/L. Further studies are required to define the optimal antenatal management of FMAIT.

Laser therapy: A randomized, controlled trial of the effects of low intensity Nd:YAG laser irradiation on lateral epicondylitis

Basford JR, Sheffield CG, Cieslak KR. Laser therapy: a randomized, controlled trial of the effects of low intensity Nd:YAG laser irradiation on lateral epicondylitis. Arch Phys Med Rehabil 2000;81:1504-10. Objective: To assess the effectiveness of low intensity laser therapy in the treatment of lateral epicondylitis. Design: A double-masked, placebo-controlled, randomized clinical trial. Setting: A physical medicine and rehabilitation clinic. Participants: Fifty-two ambulatory men and women (age range, 18-70yr) with symptomatic lateral epicondylitis of more than 30 days in duration and a normal neurologic examination. Intervention: Subjects were bloc randomized into 2 groups with a computer-generated schedule. All underwent irradiation for 60 seconds at 7 points along the symptomatic forearm 3 times weekly for 4 weeks by a masked therapist. The sole difference between the groups was that the probe of a 1.06-μm continuous wave laser emitted 204mW/cm2 (12.24J/cm2) for the treated subjects and was inactive for the control subjects. Subjects were assessed at the beginning, midpoint (session 6), and end (session 12) of treatment, as well as at follow-up 28 to 35 days after their last treatment. Main Outcome Measures: Pain in last 24 hours, tenderness to palpation, and patient's perception of change (benefit). Results: The treated and untreated groups were well matched demographically. Masking was maintained for subjects and therapists; however, the groups did not vary to a statistically significant extent in terms of the main outcome measures either during treatment or at follow-up. Secondary outcome variables, such as grasp and pinch strength, medication use, and pain with grasp and pinch, also failed to statistically differ significantly between the groups. No significant treatment side effects were noted. Conclusion: Treatment with low intensity 1.06-μm laser irradiation within the parameters of this study was a safe but ineffective treatment of lateral epicondylitis. Further research seems warranted in this controversial area. © 2000 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation

Extracorporeal Shock Wave Lithotripsy: Multicenter Study of Kidney and Upper Ureter Versus Middle and Lower Ureter Treatments

Six institutions throughout the United States participated in this study. Each center used a multifunctional flat table lithotriptor (Dornier MFL-5000) to treat 658 patients with kidney and upper ureteral stones (766 treatments) and 323 with middle and lower ureteral stones (391 treatments), for a total of 925 patients (1,157 treatments). Some patients received more than 1 treatment (that is the kidney and ureter), for a total of 981 patient events. Complete followup was available for 81% of the patients. The overall stone-free rate at followup of approximately 90 days was greater in the middle and lower ureter group (83%) than in the kidney and upper ureter group (67%). The proportion of single stones treated was greater for the former group (89.5%) than for the latter group (72%). A larger proportion (18%) of the middle and lower ureter group required 2 or more treatments to the targeted stone than did the kidney and upper ureter group (13%). Anesthesia was required or selected in only 26.7% of the kidney and upper ureteral stone patients and in 18.5% of those with middle and lower ureteral calculi, usually at the request of the patient or physician, or for performance of an adjunctive procedure. The relative safety of this treatment is demonstrated by a low overall rate of complications reported during and after treatment, including a ureteral obstruction rate of 2.1% for kidney and upper ureteral stones and 2.5% for middle and lower ureteral stones. There were no demonstrated trends in a review of laboratory data to suggest significant treatment side effects. The diastolic blood pressure increased to more than 95 mm. Hg after extracorporeal shock wave lithotripsy (ESWL*) in 6% of the kidney and upper ureteral and 4% of the middle and lower ureteral stone patients, while pretreatment hypertension resolved after ESWL in 11% of both groups.The results of this clinical evaluation indicate somewhat greater effectiveness for the specified indications of ESWL of stones in the ureter below the upper rim of the bony pelvis, as opposed to those in the kidney and upper ureter, with a low incidence of complications and side effects.

Effect of tryptophan and 5-hydroxytryptophan on the blood pressure of patients with mild to moderate hypertension

Chronic treatment with L-tryptophan (4 g/day) reduced mean blood pressure in 8 of 9 patients with mild to moderate essential hypertension. No significant side effects of treatment were observed. An additional group of 8 patients was treated chronically with L-5-hydroxytryptophan (800 mg/day), the immediate precursor of serotonin. Five of the 8 patients had a significant reduction in mean arterial pressure. No significant side effects of treatment were observed. The reduction of blood pressure accompanying treatment with L-5-hydroxytryptophan suggests that at least a portion of the antihypertensive effect of L-tryptophan is mediated via serotonin.

Total body irradiation as a secondary therapy in non-Hodgkin's lymphoma

Twenty-six patients with non-Hodgkin's lymphoma have received total body irradiation (TBI) as a secondary therapy. A response was achieved with 17 patients, in six of whom it was complete. The actuarial survival rates were 50% at one year and 42% at 30 months. Best results were achieved in those with low grade histology and in those under 60 years of age. Transient marrow toxicity was the only detected significant side-effect of treatment and although it was usually severe there were no serious sequelae. TBI should be considered as a secondary therapy in non-Hodgkin's lymphoma, regardless of previous treatment.

Stress of Formalin Treatment in Juvenile Spring Chinook Salmon (Oncorhynchus tshawytscha) and Steelhead Trout (Salmo gairdneri)

The physiological stress of 200 ppm formalin treatments at 10 C is more severe in the juvenile steelhead trout (Salmo gairdneri) than in the spring chinook salmon (Oncorhynchus tshawytscha). In the steelhead, a marked hypochloremia follows a 1-hr treatment and recovery requires about 24 hr. During longer treatments, hypercholesterolemia together with reduced regulatory precision, hypercortisolemia, alkaline reserve depletion, and hypocapnia unaccompanied by a fall in blood pH occur — suggestive of compensated respiratory alkalosis. In the spring chinook, hypochloremia and reduced plasma cholesterol regulatory precision are the significant treatment side effects but recovery requires only a few hours.Formalin treatments also cause epithelial separation, hypertrophy, and necrosis in the gills of both fishes but again, consistent with the physiological dysfunctions, these are more severe in the steelhead.